# Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma

> **NCT00992134** · PHASE2 · COMPLETED · sponsor: **St. Bortolo Hospital** · enrollment: 41 (actual)

## Conditions studied

- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** Rituximab, Bendamustine, Cytarabine

## Key facts

- **NCT ID:** NCT00992134
- **Lead sponsor:** St. Bortolo Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-06
- **Final completion:** 2012-06
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2012-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992134, "Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00992134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*